Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when CATX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPerspective Therapeutics to present interim clinical trial results at ASCO 2026
Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
medium
Company announced interim results from ongoing clinical trials will be presented at the American Society of Clinical Oncology Annual Meeting, May 29-June 2, 2026 in Chicago. Actual trial data not disclosed in the 8-K filing.
Item 8.01 verify on EDGAR → -
medium
Press release issued May 21, 2026 contains the full details of the interim results being presented at ASCO.
Exhibit 99.1 view on EDGAR →
Summary
Perspective Therapeutics announced it will present interim results from its ongoing clinical trials at the 2026 ASCO Annual Meeting in late May. The 8-K filing itself does not contain the actual trial data or efficacy metrics—only that a press release was issued announcing the presentation.
For a clinical-stage biotech, trial results can be highly material to valuation, but investors must review the attached press release or wait for the ASCO presentation to assess the data's significance. Watch for the actual ASCO presentation between May 29-June 2 and any subsequent market reaction or analyst commentary, as interim results often drive significant volatility in biotech stocks depending on whether the data meets, beats, or misses expectations.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 21, 2026, Perspective Therapeutics, Inc. issued a press release announcing certain interim results from its ongoing clinical trials that are being presented at the 2026 American Society of Clinical Oncology Annual Meeting taking place May 29-June 2, 2026 in Chicago, Illinois.
The company disclosed interim results from ongoing clinical trials that will be presented at the ASCO Annual Meeting. The 8-K does not provide the actual trial data or results, only that a press release was issued announcing them. The full details are contained in the attached press release exhibit.
Event · Item 9.01 — Financial Statements and Exhibits
Perspective Therapeutics filed an 8-K attaching a press release dated May 21, 2026; no material business event disclosed in filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 Press Release dated May 21, 2026.
The company attached a press release dated May 21, 2026 as Exhibit 99.1. The 8-K body provides no details about the press release content, so the nature and materiality of any disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 24, 2026 · How we verify